LEADER 05459nam 2200637 450 001 9910819137803321 005 20230120013010.0 035 $a(CKB)2670000000612294 035 $a(EBL)2036172 035 $a(SSID)ssj0001539989 035 $a(PQKBManifestationID)11849133 035 $a(PQKBTitleCode)TC0001539989 035 $a(PQKBWorkID)11533806 035 $a(PQKB)11453636 035 $a(MiAaPQ)EBC2036172 035 $a(Au-PeEL)EBL2036172 035 $a(CaPaEBR)ebr11049160 035 $a(CaONFJC)MIL776946 035 $a(OCoLC)912315422 035 $a(EXLCZ)992670000000612294 100 $a20150509h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe science and ethics of antipsychotic use in children /$fedited by Nina Di Pietro and Judy Illes ; contributors, Mai Berger [and twenty others] 210 1$aAmsterdam, [Netherlands] :$cAcademic Press,$d2015. 210 4$dİ2015 215 $a1 online resource (228 p.) 300 $aDescription based upon print version of record. 311 $a0-12-800481-9 311 $a0-12-800016-3 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aFront Cover; The Science and Ethics of Antipsychotic Use in Children; Copyright; Contents; Contributors; Foreword; Acknowledgments; Introduction: A Call for Partnership; References; Chapter 1: A Brief History of the Science and Ethics of Antipsychotics and Off-Label Prescribing; A New Era in Psychopharmacology Research Begins; A Second Generation Emerges; The Expansion of Antipsychotics: Off-Label Use in Children; Benefits in the Face of Risks; A Call for Partnership; References; Chapter 2: Pharmacoepidemiology of Antipsychotic Use in Canadian Children and Adolescents; Introduction 327 $aDifferences in SGA Regulation Between Canada and Other CountriesCanadian Second-Generation Antipsychotic Medications Prescription Trends for Children and Adolescents; National Prescribing Trends; Provincial Prescribing Trends; Manitoba; Nova Scotia; British Columbia; Comparing Canadian SGA Prescription Trends to those in Other Countries; Conclusions; References; Chapter 3: Do We Know If They Work and If They Are Safe: Second-Generation Antipsychotics for Treatment of Autism Spectrum ...; Introduction; Methods; Efficacy of SGAs for Children and Adolescents With ASDs 327 $aEfficacy of SGAs for Children and Adolescents With DBDsSummary of Adverse Effects and Safety Data from ASD and DBD Trials Combined; Discussion; SGAs Included in RCTs; Efficacy in ASD Trials; Efficacy in DBD trials; Critique and Ethical Considerations; Conclusion; References; ASD Studies: Aripiprazole; ASD Studies: Olanzapine; ASD Studies: Risperidone; DBD Studies: Aripiprazole; DBD Studies: Quetiapine; DBD Studies: Risperidone; Chapter 4: Ensuring the Safety of Children Treated with Second-Generation Antipsychotics; Introduction; Side Effects associated with SGA use in Children and Youth 327 $aMonitoring the Health of Children and Youth on SGAsGuidelines for Metabolic Monitoring; Recommendations for Monitoring Metabolic Changes; Height; Weight; Body Mass Index; Waist Circumference; Blood Pressure; Management of Metabolic Complications; Why Standardized Metabolic Monitoring Matters; Improving Patient Care; Educating Families; Overcoming Barriers to Completion of Monitoring; Conclusion; References; Chapter 5: Pediatric Clinical Trial Activity for Antipsychotics and the Sharing of Results: A Complex Ethical Landscape; Introduction; Patient Safety, Ethics, and Clinical Trial Regulation 327 $aThe Push for Pediatric Clinical TrialsThe Push for Clinical Trial Registration; Reporting of Results; Mapping the Landscape: Clinical Trials for Antipsychotics in Children and Youth; Methods; Results; Reflections On The Current State Of Pediatric Clinical Trials For Antipsychotics; The Landscape of Clinical Trial Activity; Developmental Gaps; The Strength of Evidence; Uniformity in Outcome Measures; Gaps in Results Reporting; Recruitment and Willingness to Participate in Research; Informed Consent; Limitations; Recommendations; References 327 $aChapter 6: Pathways to Overmedication and Polypharmacy: Case Examples from Adolescents with Fetal Alcohol Spectrum Disorders 330 $a The Science and Ethics of Antipsychotic Use in Children reviews the latest findings for the safety and efficacy of the rapidly rising incidence of antipsychotic use in children and examines tensions that are created by off-label use, both in clinical psychiatric practice and research. In the past ten years, the number of antipsychotics prescribed to children with psychiatric disorders has skyrocketed. Despite this rapid growth, most medications have been inadequately studied in children for safety or efficacy and many have serious adverse health. Measures are needed to ensure that the health 606 $aAntipsychotic drugs 606 $aChildren$xDrug use 615 0$aAntipsychotic drugs. 615 0$aChildren$xDrug use. 676 $a615.7882 702 $aDi Pietro$b Nina 702 $aIlles$b Judy 702 $aBerger$b Mai 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910819137803321 996 $aThe science and ethics of antipsychotic use in children$94002128 997 $aUNINA